| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1016/J.DIABRES.2008.04.007 |
| P698 | PubMed publication ID | 18495286 |
| P2093 | author name string | Edoardo Mannucci | |
| Matteo Monami | |||
| Niccolò Marchionni | |||
| P433 | issue | 2 | |
| P921 | main subject | meta-analysis | Q815382 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 184-189 | |
| P577 | publication date | 2008-05-20 | |
| P1433 | published in | Diabetes Research and Clinical Practice | Q15750054 |
| P1476 | title | Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis | |
| P478 | volume | 81 |
| Q35974970 | All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine |
| Q34259412 | Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. |
| Q34081331 | American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary |
| Q38318796 | Avoiding or coping with severe hypoglycemia in patients with type 2 diabetes |
| Q26800249 | Cardiovascular effects of basal insulins |
| Q92348737 | Comparison of the efficacy and safety of insulin degludec/aspart (twice-daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal-bolus therapy) |
| Q34423102 | Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy. |
| Q35570938 | Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes |
| Q45402744 | Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis |
| Q41625878 | Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece |
| Q36360045 | Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain |
| Q39738725 | Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece |
| Q58788707 | Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting |
| Q35833876 | Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective |
| Q83440839 | Current literature in diabetes |
| Q36253086 | Design and rationale of a large, international, prospective cohort study to evaluate the occurrence of malformations and perinatal/neonatal death using insulin detemir in pregnant women with diabetes in comparison with other long-acting insulins |
| Q37731629 | Diabetes and weight management |
| Q34829290 | Diabetes: glycaemic control in type 2 (drug treatments). |
| Q34084546 | Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients |
| Q37799813 | Drug-induced hypoglycaemia: an update |
| Q94156353 | Evaluation of Unit Equivalency of Insulin Glargine to Insulin Detemir in an Acute Care Setting |
| Q41260941 | Glargine and degludec: Solution behaviour of higher dose synthetic insulins. |
| Q82887442 | Hypoglycemia and insulin treatment |
| Q37921892 | Insulin analogs versus human insulin in type 2 diabetes |
| Q34421048 | Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients. |
| Q26861313 | Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues |
| Q36417868 | Insulin therapy and cancer in type 2 diabetes |
| Q33880174 | Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis |
| Q34468769 | Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study |
| Q35574560 | Management of diabetes across the course of disease: minimizing obesity-associated complications |
| Q35666228 | Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira). |
| Q34570561 | Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE) |
| Q41888093 | Optimizing weight control in diabetes: antidiabetic drug selection |
| Q36712865 | Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial |
| Q22241148 | Role of insulin in the type 2 diabetes therapy: past, present and future |
| Q28078467 | Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis |
| Q37671870 | Starting bedtime glargine versus NPH insulin in poorly controlled type 2 diabetic patients with various hyperglycemia types (fasting type or postprandial type). |
| Q38317168 | Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus |
| Q64039667 | The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen |
| Q38618376 | The past, present, and future of basal insulins |
| Q50575160 | The revised NICE draft guideline for type 2 diabetes: still a long way to go. |
| Q43298002 | The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus |
| Q89258111 | Type 2 diabetes |
| Q53647314 | [Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain]. |
| Q28077366 | rDNA insulin glargine U300 - a critical appraisal |
Search more.